Treatment Approach for Schizophrenia and Major Depressive Disorder
Schizophrenia Treatment
- The American Psychiatric Association recommends initiating antipsychotic medication immediately as first-line treatment for patients with schizophrenia, with continuous monitoring for effectiveness and side effects 1
- The American Psychiatric Association suggests considering second-generation antipsychotics such as aripiprazole, cariprazine, lurasidone, or amisulpride, which show superior efficacy for negative symptoms compared to other agents 2
- For treatment-resistant cases, the American Psychiatric Association recommends switching to clozapine, which has the strongest evidence for efficacy in this population (1B recommendation) 1
- When initiating clozapine, co-prescribe metformin 500 mg daily, titrating to 1 g twice daily over 2 weeks to attenuate weight gain, as recommended by The Lancet Psychiatry 2
- The American Psychiatric Association suggests offering long-acting injectable antipsychotics for patients with poor or uncertain adherence history, or when patients prefer this route (2B recommendation) 1
Major Depressive Disorder Treatment
- The American College of Physicians recommends selecting either cognitive behavioral therapy or a second-generation antidepressant as first-line treatment for patients with major depressive disorder, with both showing equivalent effectiveness 3
- For mild depression, the American College of Physicians suggests starting with CBT alone, specifically incorporating behavioral activation to target anhedonic symptoms 5
- For moderate to severe depression, the American College of Physicians recommends initiating either CBT or second-generation antidepressants (SSRIs or SNRIs), discussing adverse effect profiles, cost, accessibility, and patient preferences 3
- The American College of Physicians suggests choosing SSRIs or SNRIs as first-line agents, but avoiding these when anhedonia is the predominant symptom, as they show limited efficacy and may worsen anhedonia 5
- For anhedonia-predominant depression, the American College of Physicians recommends considering bupropion, which has lower rates of sexual adverse effects compared to fluoxetine and sertraline 3
- The American College of Physicians suggests continuing treatment for 4-9 months after satisfactory response for first episodes, and for ≥1 year to prevent relapse for recurrent episodes 3
- For treatment-resistant depression, the American College of Physicians recommends considering ketamine or esketamine for patients who have not responded to other treatments 6
- The American College of Physicians suggests considering electroconvulsive therapy for multiple prior treatment failures or when rapid improvement is needed 6